NFKB1 and myeloid sarcoma: The approach of targeting the activity of this pathway has also previously attracted attention in chronic inflammatory diseases such as Rheumatoid arthritis (RA) [81], Multiple Sclerosis (MS) [82] and, inflammatory bowel disease [83], in which NF-κB activity is persistently elevated.